[Multidisciplinary treatment of malignant melanoma of the nose and paranasal sinuses--with special reference to oral administration of enterosoluble BCG capsules].
In authors' clinic, seven patients with malignant melanoma of the nasal cavity and paranasal sinuses were treated with "per oral BCG" immunotherapy combined with other treatments for 3 years and 7 months from September 1978 to March, 1982. Eighty mg of BCG was enclosed in an enterosoluble capsule and administered to these patients orally once a week. Total doses of BCG administered were ranged from 2,240 mg to 11,860 mg. These treatments were effective for metastasis to the lung, but ineffective against the abdominal metastasis. Immunological parameters of these patients indicated good scores during the treatments. Mean survival time of four cases who died was 3 years and 3 months, and three other cases lived for 5 months, 11 months, and 2 years and 10 months, respectively. On the other hand, mean survival time of six historical control cases was 1 year and 10 months. Multidisciniplinary treatment was thought to be effective to extend their survival time. Three cases complained of arthralgia as a side effect by oral BCG administration.
D000328:Adult; D000368:Aged; D000510:Alpha-Globulins / Q000032:analysis; D001500:BCG Vaccine / Q000008:administration & dosage*; D002214:Capsules; D005260:Female; D006801:Humans; D007958:Leukocyte Count; D008214:Lymphocytes / Q000276:immunology; D008297:Male; D008545:Melanoma / Q000276:immunology / Q000628:therapy*; D008875:Middle Aged; D009669:Nose Neoplasms / Q000276:immunology / Q000628:therapy*; D010255:Paranasal Sinus Neoplasms / Q000276:immunology / Q000628:therapy*; D012882:Skin Tests; D005719:gamma-Globulins / Q000032:analysis
D000510:Alpha-Globulins; D001500:BCG Vaccine; D002214:Capsules; D005719:gamma-Globulins